UNSPSC 51422201: Fluocinonide

This classification denotes a therapeutic glucocorticoid with the molecular formula C26H32F2O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2W4A77YPAN, chemically known as 6.alpha.,9-difluoro-11.beta.,16.alpha., 17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16, 17-acetal with acetone, 21-acetate but generally known as fluocinonide, which bears US NIH Compound Identifier 3382. European Medicines Agency schedules Fluocinonide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07715MIG.

UNSPSC 51422201 Fluocinonide, a Commodity code, shows minimal recent state and local procurement activity directly aligned with this pharmaceutical ingredient. The two recent opportunities posted under this code—Seminole County's naloxone and drug deactivation systems bid and the Texas Health and Human Services Commission's Therapeutic Pharmacy Initiative RFI—do not involve fluocinonide procurement. Naloxone is an opioid antagonist used for overdose reversal, and the Texas HHS initiative concerns direct-to-manufacturer prescription fulfillment models; neither represents demand for fluocinonide, a corticosteroid used in dermatological and anti-inflammatory applications. The issuing bodies reflect state health agencies and county health departments, but the actual commodities being sourced fall outside the fluocinonide category.

The code shows activity primarily in Florida and Texas as of mid-2026, but the geographic and issuing-body signals are not actionable for fluocinonide vendors because the recent opportunities are unrelated to the code's nominal scope. Seminole County posted an IFB (IFB60459723LAS) on June 30, 2026, with a response deadline of July 26, 2023—a date inconsistency in the source—for naloxone and drug deactivation systems with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The Texas HHS Commission posted an RFI (HHS0017013) on April 3, 2026, seeking vendor input on direct-to-manufacturer prescription programs. Neither procurement signals near-term demand for fluocinonide from state or local buyers. Vendors in this commodity should monitor other issuing bodies and future notices more closely, as this code's recent activity does not reflect fluocinonide purchasing patterns.